Sample data collected on Cimetidine (a histamine receptor antagonist), bovine insulin, and other complex organic materials, shows how the X'Pert Pro MPD takes high-resolution screening to a new level
The X'Pert Pro MPD X-ray powder diffraction (XRPD) system from Panalytical combines rapid data collection with unsurpassed data quality.
This makes possible for the first time the use of a single analytical system for polymorph screening in combination with structural analysis.
Traditionally, screening instruments have been optimized for speed, providing only low-resolution data.
As a result, the use of a second, high-resolution analysis technique has been common.
The system offers high throughput, high-resolution screening that goes beyond pure polymorph identification to deliver semi-automatic crystallographic analysis.
The investigation of polymorphs - chemically identical substances in different crystallographic forms with possibly differing dissolution properties and varying bioavailability - is a key step in drug development.
It aids the selection of a suitable solid form for development.
In addition, because several polymorphs can have similar efficacy, it is essential that pharmaceutical companies discover and patent all polymorphs, hydrates and solvates of a drug.
XRPD is an accepted methodology for new product registrations and patent applications - an indexed XRPD pattern is frequently used to secure a patent.
